Sanofi, Regeneron drug fares well in study

... Drug Administration approved a new treatment for the disease, Pfizer Inc.'s twice-a-day pill Xeljanz. Shares of Tarrytown, N.Y.-based Regeneron closed at $276.41 on Thursday and have climbed more than 62 percent this year. U.S.-traded shares of ...

http://www.bellinghamherald.com/2013/11/22/3331420/sanofi-regeneron-drug-fares-well.html#storylink=rss